Streetbeat News

NUMIF

Numinus Wellness Inc.

http://rojoresources.com/

CEO

Allen Morishita

Industry

Testing Laboratories

Open

0.02

Mkt cap

6.2M

Volume

14K

High

0.03

P/E Ratio

-0.32

52-wk high

0.09

Low

0.02

Div yield

N/A

52-wk low

0.02

Numinus Wellness has announced the sale of its U.S. wellness clinics to Stella for $3.53 million and a partnership to develop a technology-driven clinic management solution. This move aims to enhance clinic efficiency and support mental health care providers.

Portfolio Pulse from

November 15, 2024 | 12:15 pm

The FDA has delayed the approval of MDMA-assisted psychotherapy for PTSD, requiring an additional phase 3 trial. Lykos Therapeutics is working to address the FDA's concerns. Meanwhile, other companies like Atai Life Sciences, Numinus Wellness, Compass Pathways, MindBio Therapeutics, and Awakn Life Sciences are advancing their psychedelic treatments for various psychiatric conditions.

Portfolio Pulse from Juan Spínelli

September 13, 2024 | 12:28 am

Numinus Wellness Inc. plans to acquire MedBright AI Investments Inc. to leverage AI technology for improved healthcare delivery. The acquisition aims to enhance clinical operations, reduce costs, and improve patient outcomes. Numinus will issue approximately 204.7 million shares for the deal and rebrand as Numinus Intelligence.

Portfolio Pulse from Jelena Martinovic

June 22, 2024 | 6:35 pm

Numinus Wellness (OTCQX:NUMIF) reported a decline in Q2 2024 revenue to $3.66 million from $3.89 million in Q2 2023, amid clinic reshuffling and industry trends. The company's cash position decreased to $4.8 million from $14.33 million year-over-year. Despite reduced revenues and gross profit, Numinus saw a decrease in G&A expenses and total expenses, leading to a smaller net loss compared to the same period in 2023. The company is focusing on profitability and has initiated cost containment measures, including discontinuing its unprofitable Phoenix clinic and reducing headcount by 60%. Numinus is also exploring strategic alternatives for its Canadian operations to focus on growth opportunities in the U.S., where it generated 88% of its revenue in FY2023.

Portfolio Pulse from Lara Goldstein

April 15, 2024 | 8:13 pm

PharmAla Biotech (MDXXF) and Numinus Wellness (NUMIF) have entered into a sales agreement for MDMA supply for clinical trials in Canada. Similarly, Optimi Health (OPTHF) has partnered with Tel Aviv University for MDMA research on addiction. These deals mark significant advancements in MDMA-assisted psychotherapy and addiction research, with potential impacts on mental health treatment practices.

Portfolio Pulse from Lara Goldstein

March 26, 2024 | 7:35 pm

A new study highlights the potential of psychedelics like LSD and magic mushrooms in improving sexual function. The FDA has accepted an NDA from Lykos Therapeutics for MDMA-assisted therapy for PTSD, marking a significant step towards integrating psychedelic therapies into mainstream medicine. Despite the growing interest and decriminalization efforts in several states, federal law still prohibits psilocybin. Canadian research supports psilocybin therapy for end-of-life distress, and a Washington doctor is challenging the DEA for approval to use it with terminally ill patients. The psychedelics sector, including companies like Numinus Wellness and various psychedelics stocks, shows signs of growth and investor interest.

Portfolio Pulse from Lara Goldstein

February 15, 2024 | 1:36 pm

A new study suggests suggestibility plays a role in the antidepressant effects of psilocybin therapy. The EU has allocated $7M for psychedelic research for various disorders. In Australia, the first psychedelic-assisted medical treatments in 50 years were provided. Incannex Healthcare's CEO discussed the company's role in psychedelic-assisted therapies on the Benzinga Psychedelics Podcast. Psychedelics stocks showed varied performance, with COMPASS Pathways, GH Research, and Incannex Healthcare closing higher, while others like Seelos Therapeutics and Enveric Biosciences closed lower. The AdvisorShares Psychedelics ETF (PSIL) closed at $1.43.

Portfolio Pulse from Lara Goldstein

January 27, 2024 | 3:00 pm

Numinus Wellness (OTCQX:NUMIF), a psychedelics mental healthcare company, reported a decrease in quarterly revenue and net loss, but also a significant reduction in expenses and cash used in operating activities for Q1 ending Nov. 30, 2023. The company is focusing on cost containment and has initiated a strategic review to explore options to enhance shareholder value. Numinus also reported on its three developmental programs, including clinic operations, clinical research, and therapist training, with some operations being ceased to focus on sustainable and cash flow positive activities.

Portfolio Pulse from Lara Goldstein

January 18, 2024 | 3:00 pm

The psychedelics industry is experiencing rapid growth, with the global market projected to reach $7.1 billion by 2032. The article highlights 30 influential figures in the field, including executives, scientists, and advocates, who are driving innovation and acceptance of psychedelic medicines. Among the notable individuals are Janet Qi of PurMinds Neuropharma, Dr. Anna Yusim, Kristina Spionjak of HLTH Communications, Marik Hazan of Tabula Rasa Ventures, Shayla Love, Doug Drysdale of Cybin Inc. (NYSE:CYBN), Dr. Beatriz Caiuby Labate of MAPS, Dr. David Meiri, Nataliya Vorobyeva of Hive Bio, Dr. Joseph Tucker of Enveric Biosciences (NASDAQ:ENVB), Amanda Siebert, Mattha Busby, Dennis Walker of Mycopreneur, Graham Pechenik, Rick Doblin of MAPS PBC, Jules Evans, Prof. David Nutt, Dr. Peter Grinspoon, Dr. Nolan Williams, Genevieve and Steve Jurvetson (Steve is an early VC investor in Tesla (NASDAQ:TSLA)), Reilly Capps, Payton Nyquvest of Numinus Wellness (OTC:NUMIF), Andrew Huberman, Dr. Max Wolff, Amanda Feilding, Dr. Rachel Yehuda, Dr. Mason Marks, David B. Yaden, and Dr. Robin Carhart-Harris. The article emphasizes the diverse backgrounds and contributions of these individuals to the advancement of psychedelic therapy for mental health.

Portfolio Pulse from Lara Goldstein

January 11, 2024 | 12:56 am

The Department of Defense Health Agency is funding a trial for PTSD treatment using Seelos Therapeutics' intranasal ketamine, SLS-002. Cybin Inc. reported strong efficacy in its Phase 2 trial of psilocybin derivative CYB003 for Major Depressive Disorder. Clearmind Medicine announced results from a pre-clinical trial combining its MEAI treatment with SciSparc's PEA for various disorders. Clearmind also underwent a reverse stock split to comply with Nasdaq's minimum bid price rule. Beckley Retreats is launching a new psilocybin retreat program, and Mindbloom is introducing a ketamine therapy program. Seelos Therapeutics launched a public offering, and other companies reported financial results or updates. The AdvisorShares Psychedelics ETF and several psychedelics stocks' trading performance are also highlighted.

Portfolio Pulse from Lara Goldstein

December 05, 2023 | 3:12 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.